Sandostatin LAR Description

The active substance is octreotide free peptide. 10 mg, 20 mg or 30 mg nominally 4.15% of fill weight equivalent to 4.65% of octreotide acetate.
Excipients/Inactive Ingredients: Vial: Poly(DL-lactide-co-glycolide) 78.35% of nominal fill weight; sterile mannitol 17.0% of nominal fill weight.
Prefilled syringe: Kit without vial adapter/safety needle: One prefilled syringe (solvent for parenteral use), containing: sodium carboxymethylcellulose 12.5 mg, mannitol 15 mg; water for injection qs ad 2.5 mL.
Kit with vial adapter and safety needle: One prefilled syringe (solvent for parenteral use), containing: sodium carboxymethylcellulose (14 mg), mannitol (12 mg), poloxamer 188 (4 mg); water for injection qs ad 2 mL.
Kit without vial adapter/safety needle: Powder: white to off-white powder.
Solvent for suspension for injection: clear, colorless solution.
Kit with vial adapter and safety needle: Powder: white to white with yellowish tint powder.
Solvent for suspension for injection: clear, colorless to slightly yellow or brown solution.
Sandostatin LAR is a long-acting depot injection form of octreotide. Powder (microspheres for suspension for injection) to be suspended in a vehicle immediately prior to i.m. injection.